Since inhibitors of sEH synergize well with NSAIDs, combined therapy could allow to reduce the side effects resulting from chronic intake of NSAIDs or to increase the effectiveness of treatment, especially of patients who experience stroke. The gene discussed is EPHX2; the disease is stroke disorder.